You are here : Home > Research Centers and Units > IDMIT

Infectious Diseases Models for Innovative Therapies Department (IDMIT)

​​​​​​​ Département Infectious Diseases Models for Innovative Therapies - IDMIT

Director: Dr. Roger Le Grand

Deputy Director: Denis Guillaneux

Assistant: Christelle Reverchon

Published on 1 September 2025

General Pr​esentation

The IDMIT Department of the François Jacob Institute of Biology is also, as designated by the High Council for the Evaluation of Research and Higher Education (Hcéres), the Joint Research Unit U1184/IMVA-HB (Immunology of Viral, Autoimmune, Hematological and Bacterial diseases).

This research and technological development unit is a collaborative entity between the CEA, Université Paris-Saclay, and Inserm, specializing in human infectious diseases and autoimmune disorders.

IDMIT’s research focuses on infection and immunity imaging, the identification of predictive biomarkers for treatment efficacy, and work related to CBRN (Chemical, Biological, Radiological, and Nuclear) risks.

IDMIT also coordinates the National Infrastructure for Biology and Health (INBS) IDMIT, under the joint supervision of the CEA, Université Paris-Saclay, Inserm, and the Institut Pasteur. As a key player in research and innovation in France and Europe, this infrastructure contributes to the development of new therapeutic and vaccine strategies.

​




​​
@CEA IDMIT​



Image 1bis.jpg 
                                                                @CEA IDMIT​




Objectives

The main research and technological development objectives of the IDMIT Department are to:

  • Improve understanding of the complex host-pathogen interactions,

  • Explore the molecular and cellular mechanisms, particularly those of the immune system during infectious, inflammatory, or autoimmune processes,

  • Leverage acquired knowledge to support the development of new drugs, innovative therapeutic strategies, and contribute to the next generation of vaccines,

  • Develop high predictive-value non-human primate preclinical models for studying infection, inflammation, or immune system dysfunctions in humans,

  • Improve the performance of existing vaccines and treatments,

  • Validate and/or test the efficacy of new therapeutic drugs or vaccine candidates,

  • Accelerate and facilitate the transition from preclinical models to clinical trials,

  • Ensure relevant technological developments to maintain cutting-edge research capabilities.